Evaluation of the AccuPower® RV1 Real-Time RT-PCR Kit and the AccuPower® RV1 Multiplex Kit for SARS-CoV-2 and Influenza Virus Detection
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: The AccuPower® RV1 Real-Time RT-PCR Kit (Bioneer, Korea) and AccuPower® RV1 Multiplex Kit (Bioneer) are one-step real-time reverse transcription PCR assays for detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza A and B. Methods: We clinically evaluated the AccuPower® RV1 Real-Time RT-PCR Kit and AccuPower® RV1 Multiplex Kit by comparing their results for 1,098 clinical samples. The presence of SARS-CoV-2 was confirmed using the Allplex™ 2019-nCoV Assay (Seegene, Korea) and Standard M nCoV Real-Time Detection Kit (SD Biosensor, Korea). Influenza viruses were detected using the Allplex™ Respiratory Panel 1 (Seegene). Results: The comparative positive and negative agreement values of the AccuPower® RV1 Real-Time RT-PCR Kit for SARS-CoV-2 and influenza A and B were 100%. The positive agreement of the AccuPower® RV1 Multiplex Kit was 100% for SARS-CoV-2 and 98.77% for influenza A and B. The kappa values for SARS-CoV-2 and influenza A and B were >0.99. SARS-CoV-2 was evaluated using both sputum and nasopharyngeal or oropharyngeal swabs. There was no difference in the detection rates for each type. Conclusions: The findings confirm the clinically comparable performances of the AccuPower® RV1 Real-Time RT-PCR Kit and the AccuPower® RV1 Multiplex Kit.
Abstract
Background: The AccuPower® RV1 Real-Time RT-PCR Kit (Bioneer, Korea) and AccuPower® RV1 Multiplex Kit (Bioneer) are one-step real-time reverse transcription PCR assays for detecting severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and influenza A and B. Methods: We clinically evaluated the AccuPower® RV1 Real-Time RT-PCR Kit and AccuPower® RV1 Multiplex Kit by comparing their results for 1,098 clinical samples. The presence of SARS-CoV-2 was confirmed using the Allplex™ 2019-nCoV Assay (Seegene, Korea) and Standard M nCoV Real-Time Detection Kit (SD Biosensor, Korea). Influenza viruses were detected using the Allplex™ Respiratory Panel 1 (Seegene). Results: The comparative positive and negative agreement values of the AccuPower® RV1 Real-Time RT-PCR Kit for SARS-CoV-2 and influenza A and B were 100%. The positive agreement of the AccuPower® RV1 Multiplex Kit was 100% for SARS-CoV-2 and 98.77% for influenza A and B. The kappa values for SARS-CoV-2 and influenza A and B were >0.99. SARS-CoV-2 was evaluated using both sputum and nasopharyngeal or oropharyngeal swabs. There was no difference in the detection rates for each type. Conclusions: The findings confirm the clinically comparable performances of the AccuPower® RV1 Real-Time RT-PCR Kit and the AccuPower® RV1 Multiplex Kit.
참고문헌 (16)
- Kong WH, "SARS-CoV-2 detection in patients with infiuenza-like illness", Nat Microbiol, 5, pp.675~678 (2020)
- Jing-Jing Guo, "A multiple-center clinical evaluation of a new real-time reverse transcriptase PCR diagnostic kit for SARS-CoV-2", Future Virology, 15(10), pp.673~681 (2020), Future Medicine Ltd[DOI]
- Attwood LO, "Clinical evaluation of AusDiagnostics SARS-CoV-2 multiplex tandem PCR assay", J Clin Virol, 128, pp.104448~ (2020)
- Singer BD, "COVID-19 and the next infiuenza season", Sci Adv, 6, pp.eabd0086~ (2020)
- Bai L, "Coinfection with influenza A virus enhances SARS-CoV-2 infectivity", Cell Res, 31, pp.395~403 (2021)
- Wu X, "Co-infection with SARS-CoV-2 and infiuenza A virus in patient with pneumonia, China", Emerg Infect Dis, 26, pp.1324~1326 (2020)
- Cuadrado-Payán E, "SARS-CoV-2 and infiuenza virus co-infection", Lancet, 395, pp.e84~ (2020)
- Chung HY, "Novel dual multiplex real-time RT-PCR assays for the rapid detection of SARS-CoV-2, infiuenza A", B, and respiratory syncytial virus using the BD MAX open system, 2021, pp.10, 161~166
- Mancini F, "Multiplex real-time reverse-transcription polymerase chain reaction assays for diagnostic testing of severe acute respiratory syndrome coronavirus 2 and seasonal influenza viruses : A challenge of the phase 3 pandemic setting", J Infect Dis, 223, pp.765~774 (2021)
- Clinical and Laboratory Standards Institute, "Evaluation of detection capability for clinical laboratory measurement procedures; Approved guideline—Second edition, CLSI document EP17-A2", Clinical and Laboratory Standards Institute, ~ (2012)
- Alosaimi B, "Infiuenza co-infection associated with severity and mortality in COVID-19 patients", Virol J, 18, pp.127~ (2021)
- D’Abramo A, "Acute respiratory distress syndrome due to SARS-CoV-2 and Infuenza A co-infection in an Italian patient : Mini-review of the literature", Int J Infect Dis, 97, pp.236~239 (2020)
- Konala VM, "Co-infection with Infuenza A and COVID-19", Eur J Case Rep Intern Med, 7, pp.001656~ (2020)
- Mohammadi A, "SARS-CoV-2 detection in different respiratory sites : A systematic review and meta-analysis", EBioMedicine, 59, pp.102903~ (2020)
- Yu F, "Comparative evaluation of three preprocessing methods for extraction and detection of infiuenza A virus nucleic acids from sputum", Front Med, 5, pp.56~ (2018)
- Lin C, "Comparison of throat swabs and sputum specimens for viral nucleic acid detection in 52 cases of novel coronavirus(SARS-Cov-2)-infected pneumonia(COVID-19)", Clin Chem Lab Med, 58, pp.1089~1094 (2020)